Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A.

Cancer. 2009 Oct 1;115(19):4504-13. doi: 10.1002/cncr.24528.

PMID:
19634157
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, Burtness B, Forastiere AA.

J Clin Oncol. 2013 Apr 10;31(11):1405-14. doi: 10.1200/JCO.2012.45.4272. Epub 2013 Mar 4.

PMID:
23460714
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR.

Ann Oncol. 1999 Jan;10(1):119-22.

PMID:
10076732
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Shin DM, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, Clayman G, Lee JJ, Ang KK, Lippman SM, Hong WK.

Cancer. 2001 Apr 1;91(7):1316-23.

PMID:
11283932
[PubMed - indexed for MEDLINE]
5.

A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).

Limaye S, Riley S, Zhao S, O'Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R.

Oral Oncol. 2013 Aug;49(8):835-41. doi: 10.1016/j.oraloncology.2013.04.010. Epub 2013 May 30.

PMID:
23727257
[PubMed - indexed for MEDLINE]
6.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA; SPECTRUM investigators.

Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.

PMID:
23746666
[PubMed - indexed for MEDLINE]
7.

Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.

Knoedler M, Gauler TC, Gruenwald V, Matzdorff A, Schroeder M, Dietz A, Jordan WO, Arnold D, Hennemann B, Hofele C, Weissinger F, Eberhardt W, Keilholz U.

Oncology. 2013;84(5):284-9. doi: 10.1159/000345453. Epub 2013 Feb 26.

PMID:
23445718
[PubMed - indexed for MEDLINE]
8.

Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).

Caponigro F, Massa E, Manzione L, Rosati G, Biglietto M, De Lucia L, Sguotti C, Sganga P, Avallone A, Comella P, Mantovani G, Comella G.

Ann Oncol. 2001 Feb;12(2):199-202.

PMID:
11300324
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.

Langer CJ, Li Y, Jennings T, DeConti RC, Nair S, Cohen RB, Forastiere AA; Eastern Cooperative Oncology Group.

Cancer Invest. 2004;22(6):823-31.

PMID:
15641479
[PubMed - indexed for MEDLINE]
10.

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.

Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group.

Ann Oncol. 2008 May;19(5):977-83. doi: 10.1093/annonc/mdm591. Epub 2008 Feb 21.

PMID:
18296423
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.

Specht L, Larsen SK, Hansen HS.

Ann Oncol. 2000 Jul;11(7):845-9.

PMID:
10997812
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.

Vermorken JB, Licitra L, Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC.

Eur J Cancer. 2013 Sep;49(13):2877-83. doi: 10.1016/j.ejca.2013.05.002. Epub 2013 May 30.

PMID:
23726971
[PubMed - indexed for MEDLINE]
13.

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.

Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J.

Cancer. 1999 Dec 1;86(11):2364-9.

PMID:
10590379
[PubMed - indexed for MEDLINE]
14.

Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.

Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA.

J Clin Oncol. 2002 Mar 15;20(6):1593-9.

PMID:
11896109
[PubMed - indexed for MEDLINE]
Free Article
15.

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E.

Cancer Biol Ther. 2006 Jul;5(7):766-70. Epub 2006 Jul 2.

PMID:
16760642
[PubMed - indexed for MEDLINE]
Free Article
16.

Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.

Chang PM, Tzeng CH, Chen MH, Tsao CJ, Su WC, Hwang WS, Chang YF, Chang SY, Yang MH.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1477-84. doi: 10.1007/s00280-011-1645-5. Epub 2011 Apr 12.

PMID:
21484308
[PubMed - indexed for MEDLINE]
17.

A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R.

Anticancer Res. 2006 Jan-Feb;26(1B):585-90.

PMID:
16739325
[PubMed - indexed for MEDLINE]
Free Article
18.

Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer.

Kucukzeybek Y, Gorumlu G, Karaca B, Erten C, Cengiz E, Kemal Gul M, Karabulut B, Uslu R, Sanli UA, Goker E.

J BUON. 2008 Apr-Jun;13(2):199-203.

PMID:
18555465
[PubMed - indexed for MEDLINE]
19.

Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.

Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF.

Cancer Invest. 2007 Apr-May;25(3):182-8.

PMID:
17530488
[PubMed - indexed for MEDLINE]
20.

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group.

J Clin Oncol. 2005 Dec 1;23(34):8646-54. Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.

PMID:
16314626
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk